Marker Therapeutics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumors. The company's core product platform, Multi-Antigen Recognizing T cells (MAR-T), involves a non-genetically modified approach that selectively expands natural tumor-specific T cells from patients’ blood to recognize multiple tumor-associated antigens, thereby reducing tumor escape and improving safety profiles compared to engineered therapies. Its lead product candidate, MT-601, is a MAR-T cell therapy targeting six tumor antigens prevalent in lymphoma, currently under investigation in the ongoing Phase 1 APOLLO clinical trial for patients who have relapsed after or are ineligible for anti-CD19 CAR-T cell therapies. Marker Therapeutics also develops off-the-shelf (OTS) MAR-T cell therapies to expand clinical applicability and accessibility. Founded at Baylor College of Medicine and headquartered in Houston, Texas, Marker Therapeutics operates primarily in the United States but its technology has global development implications. Recent major developments include the initiation of the RAPID study to evaluate the off-the-shelf MAR-T product MT-401, partnerships for cGMP manufacturing scale-up with Cellipont Bioservices to support production for clinical trials, and successful capital raises such as a private placement in 2024 securing $16.1 million alongside $13 million in non-dilutive funding from the Cancer Prevention and Research Institute of Texas (CPRIT). The company reports encouraging clinical results from its APOLLO study with an observed objective response rate of 66% and durable complete responses in non-Hodgkin lymphoma patients. Marker Therapeutics has demonstrated progress in addressing the unmet needs of patients with relapsed or refractory lymphoma, positioning its platform as a differentiated next-generation immunotherapy approach. Marker Therapeutics continues to focus on expanding its clinical pipeline and advancing its multi-antigen cell therapy platform, aiming to provide effective and durable immunotherapies with improved safety and manufacturability compared to current treatments. Its strategy includes broadening indications across hematologic and solid tumors, leveraging strategic alliances for research, manufacturing, and clinical development to enhance its market position within the biotechnology and pharmaceutical sectors. The company maintains a commitment to innovation in non-engineered T cell therapies that harness natural immune responses for cancer treatment.
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?
5 Small Drug Stocks to Buy as Industry Recovery Picks Up
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Marker Therapeutics Stock Drops After Report About Lymphoma Treatment
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma